{"title":"Safety and Efficacy of Two Venous Closure Devices Compared With Manual Compression After Atrial Fibrillation Ablation","authors":"Satoko Shiomi, Kenichi Tokutake, Ui Takato, Ryutaro Sakurai, Yoshito Yamazaki, Takuya Matsumoto, Hidenori Sato, Hirotsuna Oseto, Masaaki Yokoyama, Seigo Yamashita, Teiichi Yamane, Michifumi Tokuda","doi":"10.1002/joa3.70442","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>VASCADE MVP device has garnered attention as a novel femoral venous closure device. Manual compression (MC) is associated with prolonged bed rest and significant patient discomfort. Although Perclose ProGride/ProStyle device reduces bed rest duration, it can result in severe puncture site complications. The adoption of VASCADE MVP is anticipated to reduce the incidence of puncture site complications and facilitate early patient mobilization.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A total of 858 patients undergoing catheter ablation were included in this study (MC: <i>n</i> = 196; Perclose: <i>n</i> = 547; VASCADE: <i>n</i> = 115). Perclose device was introduced in January 2018, and VASCADE device in September 2024. Venous closure devices were employed for all suitable femoral puncture sheaths. In the MC group, compression was released after 7 h or the following morning; in the Perclose group after 4 h and in the VASCADE group after three or 4 h. Total post-procedure time and vascular complications were compared among the groups.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The total post-procedure time was significantly shorter with VASCADE compared to Perclose and MC (22.6 ± 8.9 min vs. 29.6 ± 8.2 min and 30.4 ± 9.3 min, <i>p</i> < 0.001). The incidence of re-bleeding was comparable between Perclose and VASCADE (11% vs. 13%, <i>p</i> = 0.787). No serious complications were observed in VASCADE group, whereas three patients (1%) in Perclose group experienced major complications.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>The use of VASCADE devices safely reduced both total post-procedure time and bedrest times for complete hemostasis, without an associated increase in complications.</p>\n </section>\n </div>","PeriodicalId":15174,"journal":{"name":"Journal of Arrhythmia","volume":"42 4","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2026-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/joa3.70442","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Arrhythmia","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/joa3.70442","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Background
VASCADE MVP device has garnered attention as a novel femoral venous closure device. Manual compression (MC) is associated with prolonged bed rest and significant patient discomfort. Although Perclose ProGride/ProStyle device reduces bed rest duration, it can result in severe puncture site complications. The adoption of VASCADE MVP is anticipated to reduce the incidence of puncture site complications and facilitate early patient mobilization.
Methods
A total of 858 patients undergoing catheter ablation were included in this study (MC: n = 196; Perclose: n = 547; VASCADE: n = 115). Perclose device was introduced in January 2018, and VASCADE device in September 2024. Venous closure devices were employed for all suitable femoral puncture sheaths. In the MC group, compression was released after 7 h or the following morning; in the Perclose group after 4 h and in the VASCADE group after three or 4 h. Total post-procedure time and vascular complications were compared among the groups.
Results
The total post-procedure time was significantly shorter with VASCADE compared to Perclose and MC (22.6 ± 8.9 min vs. 29.6 ± 8.2 min and 30.4 ± 9.3 min, p < 0.001). The incidence of re-bleeding was comparable between Perclose and VASCADE (11% vs. 13%, p = 0.787). No serious complications were observed in VASCADE group, whereas three patients (1%) in Perclose group experienced major complications.
Conclusion
The use of VASCADE devices safely reduced both total post-procedure time and bedrest times for complete hemostasis, without an associated increase in complications.
VASCADE MVP装置作为一种新型股静脉闭合装置引起了人们的关注。手动按压(MC)与长时间卧床休息和明显的患者不适有关。虽然Perclose ProGride/ProStyle装置减少了卧床休息时间,但它可能导致严重的穿刺部位并发症。采用VASCADE MVP有望减少穿刺部位并发症的发生率,并促进患者早期活动。方法共纳入858例导管消融患者(MC: n = 196; Perclose: n = 547; VASCADE: n = 115)。Perclose设备于2018年1月推出,VASCADE设备于2024年9月推出。所有合适的股穿刺鞘均采用静脉封闭装置。MC组于7 h后或次日早晨解除压迫;4 h后Perclose组和3、4 h后VASCADE组。比较两组患者术后总时间和血管并发症。结果与Perclose和MC相比,VASCADE的总术后时间明显缩短(22.6±8.9 min vs. 29.6±8.2 min和30.4±9.3 min, p < 0.001)。Perclose和VASCADE的再出血发生率相当(11%比13%,p = 0.787)。VASCADE组无严重并发症,Perclose组有3例(1%)出现严重并发症。结论VASCADE装置的使用安全减少了完全止血的总术后时间和卧床时间,没有增加并发症。